C3 glomerulopathy: experience of a pediatric nephrology center

References

• Fakhouri F, Frémeaux-Bacchi V, Noël LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010 Aug;6(8):494–499. Epub 2010 Jul 6. Review. PMID: 20606628.
   Google Scholar
• Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013 Dec;84(6):1079–1089. Epub 2013 Oct 30. PMID: 24172683.
   Google Scholar
• Rovin BH, Caster DJ, Cattran DC, et al.. Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019 Feb;95(2):281–295. PMID: 30665569.
   Google Scholar
• Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee on screening and management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017 Sep;140(3):e20171904. Epub 2017 Aug 21. PMID: 30177515.
   Google Scholar
• Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629–637. Epub 2009 Jan 21. PMID: 19158356.
   Google Scholar
• Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007 May;71(10):1028–1035. Epub 2007 Mar 28. PMID: 17396113.
   Google Scholar
• Häffner K, Michelfelder S, Pohl M. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol. 2015 Nov;30(11):1951–1959. Epub 2015 May 19. PMID: 25986912.
   Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169–2181. PMID: 23738544.
   Google Scholar
• Viswanathan GK, Nada R, Kumar A, et al. Clinico-pathologic spectrum of C3 glomerulopathy – an Indian experience. Diagn Pathol. 2015 Mar 17;10:6.
   Google Scholar
• Medjeral-Thomas NR, O’Shaughnessy MM, O’Regan JA, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014 Jan 9;(1):46–53. Epub 2013 Oct 31. PMID: 24178974. Doi:10.2215/CJN.04700513
   Google Scholar
• Ravindran A, Fervenza FC, Smith RJH, et al. C3 glomerulopathy: ten years’ experience at Mayo clinic. Mayo Clin Proc. 2018 Aug;93(8):991–1008. PMID: 30077216. .
   Google Scholar
• Holle J 1, Berenberg-Goßler L, Wu K, et al. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol. 2018 Dec;33(12):2289–2298. Epub 2018 Sep 20. PMID: 30238151.
   Google Scholar
• Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012 Aug;82(4):465–473. PMID: 22673887.
   Google Scholar
• Hou J, Markowitz GS, Bomback AS, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014 Feb;85(2):450–456. Epub 2013 Sep 25. PMID: 24067430.
   Google Scholar
• Larsen CP, Walker PD. Redefining C3 glomerulopathy: ‘C3 only’ is a bridge too far. Kidney Int. 2013 Feb;83(2):331–332. No abstract available. PMID: 23364589. .
   Google Scholar
• Goodship TH, Cook HT, Fakhouri F, et al.; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2017 Mar;91(3):539–551. Epub 2016 Dec 16. PMID: 27989322.
   Google Scholar
• Le Quintrec M, Lapeyraque AL, Lionet A, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis. 2018 Jul;72(1):84–92. Epub 2018 Feb 9. PMID: 29429752. .
   Google Scholar